HypoSkin®
SKIN MODEL FOR SUBCUTANEOUS INJECTIONS
FIRST MODEL FOR SUBCUTANEOUS INJECTIONS
Currently, HypoSkin is the only alternative to animal testing for subcutaneous injections.
INJECTABLE REAL HUMAN SKIN
The HypoSkin model contains all three layers of human skin for predictive studies.
LIVE HUMAN SKIN RESPONSE
Genoskin’s patented matrix and culture medium keep the skin model alive for 7+ days.
ADAPTED TO YOUR NEEDS
HypoSkin is available in different formats and can be used for subcutaneous and topical applications.
HypoSkin: The only human skin model to study subcutaneous injections
Genoskin has developed an ex vivo human skin biopsy with fat tissue. HypoSkin contains the three skin layers: epidermis, dermis, and hypodermis. Currently, many compounds under development or already on the market are administrated subcutaneously. They are, for instance, cancer treatments, anti-inflammatory agents,and cosmetic fillers. HypoSkin is an ex vivo model to study compound absorption, first-pass catabolism, and toxicity in the subcutaneous tissue.
The HypoSkin project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 816289 (SME Instrument)
HypoSkin: The need for in vitro models for subcutaneous injections
To date, there are no in vitro biological models to test the effects of compound injection in the subcutaneous tissue. Then, researchers generally test formulations in vivo on animals, even though their skin and subcutaneous fat tissue are different from humans. As a result, the absence of more pertinent models makes it difficult to evaluate and optimize a compound’s formulation before clinical trials. Therefore, to develop efficient drugs for subcutaneous injection, there’s a strong need for in vitro experimental models that closely mimic human tissue structure and physiology.
Hypo-InflammaSkin: a psoriasis model to study subcutaneous injections of anti-inflammatory biologics
a proof-of-concept case study
The HypoSkin technology was combined with the InflammaSkin model to evaluate the efficacy of subcutaneous psoriasis biologics adalimumab.
HypoSkin® comes in different sizes and thickness to meet any subcutaneous injections need
HypoSkin® comes in a range of formats varying in biopsy diameter and fat tissue thickness to assess skin response to subcutaneous injections and topical or systemic administration.
Please note that HypoSkin® assays are performed in house through a broad range of services. Therefore, we would be happy to discuss with you to understand yours needs and help your project move forward: contact us for additional information.
| SUBCUTANEOUS INJECTION | TOPICAL ADMINISTRATION | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| REFERENCE | DESCRIPTION | Ø | HYPODERMIS THICKNESS | RECOMMENDED INJECTION VOLUME | WORKING SURFACE | RECOMMENDED TOPICAL VOLUME | EX VIVO CULTURE DURATION | PLATE FORMAT | REQUIRED VOLUME OF MEDIUM/DAY | MINIMUM ORDER |
| HPS001-5 | HypoSkin® | 11 mm | 5 mm | - | 0.5 cm2 | 5-20 uL | 7 days | 12 wells | 1 mL | 12 wells |
| HPS001-10 | 10 mm | 20 uL | ||||||||
| HPS002-5 | HypoSkin® Medium | 15 mm | 5 mm | - | 1.13 cm2 | 25-45 uL | 7 days | 6 wells | 2 mL | 12 wells |
| HPS002-10 | 10 mm | 40 uL | ||||||||
| HPS003-5 | HypoSkin® Large | 20 mm | 5 mm | - | 1.76 cm2 | 50-70 uL | 7 days | 6 wells | 2 mL | 12 wells |
| HPS003-10 | 10 mm | 100 uL | ||||||||
| HPS004-5 | HypoSkin® XL | 23 mm | 5 mm | - | 2.54 cm2 | 100-200 uL | 5 days | 6 wells | 3 mL | 12 wells |
| HPS004-10 | 10 mm | 125 uL | ||||||||
